Piper Jaffray Cos. reissued their neutral rating on shares of Clovis Oncology Inc. (NASDAQ:CLVS) in a research report report published on Wednesday. They currently have a $42.00 price target on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. reiterated a hold rating and set a $13.00 price objective on shares of Clovis Oncology in a report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Clovis Oncology from a hold rating to a buy rating and set a $18.00 price objective on the stock in a report on Thursday, August 11th. SunTrust Banks Inc. started coverage on shares of Clovis Oncology in a report on Friday, August 5th. They set a buy rating and a $25.00 price objective on the stock. Credit Suisse Group AG restated a hold rating on shares of Clovis Oncology in a report on Tuesday, July 12th. Finally, Stifel Nicolaus restated a buy rating and issued a $30.00 target price on shares of Clovis Oncology in a report on Thursday, June 30th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Clovis Oncology has an average rating of Buy and an average price target of $36.39.
Clovis Oncology (NASDAQ:CLVS) opened at 31.81 on Wednesday. The firm’s market capitalization is $1.22 billion. The firm has a 50-day moving average price of $31.11 and a 200 day moving average price of $19.16. Clovis Oncology has a 52-week low of $11.57 and a 52-week high of $109.18.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the consensus estimate of ($2.13) by $0.06. During the same quarter last year, the business posted ($2.10) EPS. Analysts forecast that Clovis Oncology will post ($9.25) EPS for the current year.
Large investors have recently modified their holdings of the company. Boxer Capital LLC bought a new position in Clovis Oncology during the second quarter worth $6,174,000. Palo Alto Investors LLC increased its position in Clovis Oncology by 9.9% in the second quarter. Palo Alto Investors LLC now owns 3,804,088 shares of the biopharmaceutical company’s stock worth $52,192,000 after buying an additional 342,723 shares in the last quarter. State Street Corp increased its position in Clovis Oncology by 21.2% in the first quarter. State Street Corp now owns 1,797,874 shares of the biopharmaceutical company’s stock worth $34,525,000 after buying an additional 313,893 shares in the last quarter. Vanguard Group Inc. increased its position in Clovis Oncology by 7.7% in the second quarter. Vanguard Group Inc. now owns 2,405,468 shares of the biopharmaceutical company’s stock worth $33,003,000 after buying an additional 171,047 shares in the last quarter. Finally, Deerfield Management Co. bought a new position in Clovis Oncology during the second quarter worth $2,326,000. 98.50% of the stock is owned by institutional investors and hedge funds.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.